199 related articles for article (PubMed ID: 23571382)
1. DEK depletion negatively regulates Rho/ROCK/MLC pathway in non-small cell lung cancer.
Wang J; Sun L; Yang M; Luo W; Gao Y; Liu Z; Qiu X; Wang E
J Histochem Cytochem; 2013 Jul; 61(7):510-21. PubMed ID: 23571382
[TBL] [Abstract][Full Text] [Related]
2. The miR-1204 regulates apoptosis in NSCLC cells by targeting DEK.
Qian Z; Yang J; Liu H; Yin Y; Hou L; Hu H
Folia Histochem Cytobiol; 2019; 57(2):64-73. PubMed ID: 31246264
[TBL] [Abstract][Full Text] [Related]
3. Significance of DEK overexpression for the prognostic evaluation of non-small cell lung carcinoma.
Liu X; Qi D; Qi J; Mao Z; Li X; Zhang J; Li J; Gao W
Oncol Rep; 2016 Jan; 35(1):155-62. PubMed ID: 26530274
[TBL] [Abstract][Full Text] [Related]
4. E-cadherin negatively regulates neoplastic growth in non-small cell lung cancer: role of Rho GTPases.
Asnaghi L; Vass WC; Quadri R; Day PM; Qian X; Braverman R; Papageorge AG; Lowy DR
Oncogene; 2010 May; 29(19):2760-71. PubMed ID: 20228844
[TBL] [Abstract][Full Text] [Related]
5. CHD4 mediates proliferation and migration of non-small cell lung cancer via the RhoA/ROCK pathway by regulating PHF5A.
Xu N; Liu F; Wu S; Ye M; Ge H; Zhang M; Song Y; Tong L; Zhou J; Bai C
BMC Cancer; 2020 Mar; 20(1):262. PubMed ID: 32228507
[TBL] [Abstract][Full Text] [Related]
6. LncNORAD interference inhibits tumor growth and lung cancer cell proliferation, invasion and migration by down-regulating CXCR4 to suppress RhoA/ROCK signaling pathway.
Wu Y; Shen QW; Niu YX; Chen XY; Liu HW; Shen XY
Eur Rev Med Pharmacol Sci; 2020 May; 24(10):5446-5455. PubMed ID: 32495879
[TBL] [Abstract][Full Text] [Related]
7. Deleted in liver cancer 1 (DLC1) negatively regulates Rho/ROCK/MLC pathway in hepatocellular carcinoma.
Wong CC; Wong CM; Ko FC; Chan LK; Ching YP; Yam JW; Ng IO
PLoS One; 2008 Jul; 3(7):e2779. PubMed ID: 18648664
[TBL] [Abstract][Full Text] [Related]
8. Increase in cell motility by carbon ion irradiation via the Rho signaling pathway and its inhibition by the ROCK inhibitor Y-27632 in lung adenocarcinoma A549 cells.
Murata K; Noda SE; Oike T; Takahashi A; Yoshida Y; Suzuki Y; Ohno T; Funayama T; Kobayashi Y; Takahashi T; Nakano T
J Radiat Res; 2014 Jul; 55(4):658-64. PubMed ID: 24659807
[TBL] [Abstract][Full Text] [Related]
9. E1AF/PEA3 activates the Rho/Rho-associated kinase pathway to increase the malignancy potential of non-small-cell lung cancer cells.
Hakuma N; Kinoshita I; Shimizu Y; Yamazaki K; Yoshida K; Nishimura M; Dosaka-Akita H
Cancer Res; 2005 Dec; 65(23):10776-82. PubMed ID: 16322223
[TBL] [Abstract][Full Text] [Related]
10. p21-activated kinase 2 binds to transcription factor SOX2 and up-regulates DEK to promote the progression of lung squamous cell carcinoma.
Xie S; Wan X; Chen S; Hu Y; Liu X
Lab Invest; 2022 Oct; 102(10):1109-1120. PubMed ID: 35821094
[TBL] [Abstract][Full Text] [Related]
11. MiR-31 Regulates Rho-Associated Kinase-Myosin Light Chain (ROCK-MLC) Pathway and Inhibits Gastric Cancer Invasion: Roles of RhoA.
Chen Z; Liu S; Xia Y; Wu K
Med Sci Monit; 2016 Dec; 22():4679-4691. PubMed ID: 27904131
[TBL] [Abstract][Full Text] [Related]
12. The small GTPase RhoA has greater expression in small cell lung carcinoma than in non-small cell lung carcinoma and contributes to their unique morphologies.
Varker KA; Phelps SH; King MM; Williams CL
Int J Oncol; 2003 Mar; 22(3):671-81. PubMed ID: 12579323
[TBL] [Abstract][Full Text] [Related]
13. DEK promotes the proliferation and invasion of lung cancers and indicates poor prognosis in lung adenocarcinomas.
Yang MQ; Bai LL; Lei L; Zheng YW; Wang Z; Li ZH; Liu CC; Huang WJ; Xu HT
Oncol Rep; 2020 Apr; 43(4):1338-1348. PubMed ID: 32020224
[TBL] [Abstract][Full Text] [Related]
14. Promotion of cell proliferation by the proto-oncogene DEK enhances oral squamous cell carcinogenesis through field cancerization.
Nakashima T; Tomita H; Hirata A; Ishida K; Hisamatsu K; Hatano Y; Kanayama T; Niwa A; Noguchi K; Kato K; Miyazaki T; Tanaka T; Shibata T; Hara A
Cancer Med; 2017 Oct; 6(10):2424-2439. PubMed ID: 28834425
[TBL] [Abstract][Full Text] [Related]
15. High expression of oncoprotein DEK predicts poor prognosis of small cell lung cancer.
Wang X; Lin L; Ren X; Lin Z; Li Z; Li C; Jin T
Int J Clin Exp Pathol; 2014; 7(8):5016-23. PubMed ID: 25197373
[TBL] [Abstract][Full Text] [Related]
16. The human DEK oncogene stimulates β-catenin signaling, invasion and mammosphere formation in breast cancer.
Privette Vinnedge LM; McClaine R; Wagh PK; Wikenheiser-Brokamp KA; Waltz SE; Wells SI
Oncogene; 2011 Jun; 30(24):2741-52. PubMed ID: 21317931
[TBL] [Abstract][Full Text] [Related]
17. Role of the DEK oncogene in the development of squamous cell carcinoma.
Ishida K; Nakashima T; Shibata T; Hara A; Tomita H
Int J Clin Oncol; 2020 Sep; 25(9):1563-1569. PubMed ID: 32656741
[TBL] [Abstract][Full Text] [Related]
18. O-GlcNAcylation promotes migration and invasion in human ovarian cancer cells via the RhoA/ROCK/MLC pathway.
Niu Y; Xia Y; Wang J; Shi X
Mol Med Rep; 2017 Apr; 15(4):2083-2089. PubMed ID: 28259907
[TBL] [Abstract][Full Text] [Related]
19. PKC-β exacerbates in vitro brain barrier damage in hyperglycemic settings via regulation of RhoA/Rho-kinase/MLC2 pathway.
Srivastava K; Shao B; Bayraktutan U
J Cereb Blood Flow Metab; 2013 Dec; 33(12):1928-36. PubMed ID: 23963366
[TBL] [Abstract][Full Text] [Related]
20. IRAK1 is a novel DEK transcriptional target and is essential for head and neck cancer cell survival.
Adams AK; Bolanos LC; Dexheimer PJ; Karns RA; Aronow BJ; Komurov K; Jegga AG; Casper KA; Patil YJ; Wilson KM; Starczynowski DT; Wells SI
Oncotarget; 2015 Dec; 6(41):43395-407. PubMed ID: 26527316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
